Beacon Therapeutics raises $120M for ophthalmic gene therapy
Beacon Therapeutics recently raised $120M in funding, with participation from Syncona Limited and Oxford Science Enterprises, among others. The Oxford, UK-based company focuses on ophthalmic gene therapy and intends to use the funds to progress its pipeline to key value inflection points.
Founded in 2023 by a highly experienced leadership team with decades of ophthalmic gene therapy experience, including David Fellows, Dr.
Nadia Waheed, and Dr. Abraham Scaria, Beacon Therapeutics aims to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Its lead development candidate, AGTC-501, is currently in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men.
The company's second pre-clinical asset focuses on cone-rod dystrophy (CRD), a condition caused by a null mutation in the Cadherin Related Family Member 1 (CDHR1) gene. This program was licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford, who will become a key scientific advisor to the company and join the board of directors. With facilities in London, Boston, and Florida, Beacon Therapeutics is well-positioned to advance its pipeline and make a positive impact on the lives of those affected by retinal diseases.
They've invested in Beacon Therapeutics
Get to know these Biotech investors
Click here for a full list of 6,528+ startup investors in the UK